Healthcare Active Stocks: AstraZeneca plc (ADR) (NYSE:AZN), NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD)

FB Nasdaq FB Facebook

AstraZeneca Plc (ADR) (NYSE:AZN), in the headlines for spurning buyout offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world’s largest meeting of cancer doctors. AstraZeneca plc (ADR) (NYSE:AZN) stock performance was -0.83% in last session and finished the day at $72.76. Traded volume was 5.14million shares in the last session and the average volume of the stock remained 5.04million shares. The beta of the stock remained 0.50.

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has finally put a full-stop on the rumors that were spreading like fire in the industry. As per the rumors, it was expected that Shire PLC (ADR) (NASDAQ:SHPG) was considering to buy NPS Pharmaceuticals. NPS made it clear that it has not received any offer from Shire. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) dropped -0.95 percent to $32.29 Tuesday on volume of 5.34million shares. The intra-day range of the stock was $31.50 to $33.79. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has a market capitalization of $3.43billion.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on June 2 announced longer-term follow up from its Phase 1 and pivotal Phase 2 trials of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The studies now show that with a median follow-up of 42.5 months for chronic-phase CML (CP-CML) patients in the Phase 1 trial, Iclusig continues to demonstrate anti-leukemic activity in those who had limited treatment options, and that deep and durable responses have been maintained in CP-CML patients in the PACE trial with 87% estimated to remain in major cytogenetic response (MCyR) at two years. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on June 03, 2014 reported a decrease of -3.60% to the closing price of $6.69. Its fifty two weeks range is $2.15 -$23.00. The total market capitalization recorded $1.25billion. The overall volume in the last trading session was 7.08million shares. In its share capital, ARIA has 186.80million outstanding shares.

Gilead Sciences Inc. (NASDAQ:GILD) announced updated interim results of a Phase 2 study (Study 102) evaluating GS-9973, its investigational oral inhibitor of spleen tyrosine kinase (Syk), for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). In this study, single-agent treatment with GS-9973 achieved an overall response rate of 49%, with an estimated progression-free survival (PFS) rate at 24 weeks of 70%. On Tuesday, shares of Gilead Sciences, Inc. (NASDAQ:GILD) advanced 1.23% to close the day at $82.55. Company return on investment (ROI) is 18.70% and its monthly performance is recorded as 6.23%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly revenue growth is -0.47%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone